Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Immunovant Inc. Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43 (market cap $136.17M), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Immunovant Inc. Common Stock is far larger — about 48.6× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is more actively traded (88,095 versus 1,131,364). Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 60 Days and Immunovant Inc. Common Stock for 0 Days on average.
| GPTY | IMVT | |
|---|---|---|
Market Cap | $136.17M | $6.62B |
Volume | 88,095 | 1,131,364 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $44.96 |
52-Week Low | $34.73 | $17.03 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $5.72B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
